1. •Ganesh Padhi (B047)
•Richansh Kumar(B038)
•Ritesh Kamal(B032)
•Sushant Kumar(B039)
•Mayank Shukla(B055)
•B Kushal Kumar(B036)

2. Pharmaceutical sector
 United States-largest market with $289 billion annual
sales
 EU and Japan are the next big markets in sales
 Markets like china, south Korea ,Russia and Mexico are
growing at 81%.
 India- 3rd largest producer, Cardiovascular-50% &
Diabetes -22%,Projected growth - $ 77 billion by 2012

3. Progress towards health-related MDGs
 Eradication of Hunger – Improvement in
nutrition of undernourished children
 Reduction in Child Mortality at 2.7% every
year
 Maternal Mortality Ratio(MMR) decreased by
34%
 Fighting HIV/AIDS, tuberculosis and malaria

4. Contd…
 Increase in population with better sanitation and
safe drinking water from 77% to 87%
 Better access to affordable essential medicines in
developing countries

5. Transparency
Public
Corruption
private
partnerships
Ethical
promotion Quality of
and medicines
marketing
Issues in
Pricing
discounts pharma
Clinical trails
and sector
donations
Management
Patents and , Monitoring
licenses and
Accountabilit
Policy y
Neglected influence
Medicines for
diseases Advocacy
disadvantage
d individuals and
and lobbying
community

6. About Astrazeneca
 World’s fifth largest pharmaceutical company
 Dedicated to research, development , manufacturing
and marketing of medicines in over 100 countries.
 Committed to sustainable development of business

7. Astrazeneca’s CSR approach
 Stakeholder based approach
 Mainly targeted employees
 Other stakeholders were suppliers, global
community, environment and customers.

8. Employees
 Workforce diversity
 Work-life balance
 Safety, health and well being
 Health screening and other health activities

9. Suppliers
 Continuing risk assessments of suppliers
 Rolling out a programme of onsite audits of key
suppliers
 Implementing plans to improve standards with certain
suppliers
 Following up and verifying that progress is being made
with suppliers
 Training staff on their standards

10. Customers
 Access to medicines for vulnerable individuals
 AstraZeneca's Young Health Programme for 10-19
years of children
 Community sponsorships and charitable donations
 Patient assistance programmes to avail medicines free
or at reduced prices.

11. Others
Global community
 Disaster relief
Environment
 Reduction in Greenhouse gas footprint
 Waste reduction
 Reduction in water usage
 Product environmental improvement
 Improvement in supply chain

12. Critical analysis
 Stakeholder approach
 Business responsibilities

13. Stakeholder approach
 Employees given more importance
 Suppliers have been maintained properly by adhering
to global standards
 Some activities favoring environmental sustainability
 Special focus on access to medicines for needy and
disadvantaged individuals
 Very few activities for global community and almost
nothing for the local community

14. Business responsibilities
 Economic responsibilities – successful
 Legal responsibilities – fulfilled to considerable extent
 Ethical responsibilities – few activities ,needs to
implement more activities and take it to a large scale
 Philanthropic responsibilities – nothing spectacular
done as of yet

15. Conclusion
 Addresses concerns of majority of stakeholders
 Needs to work more towards suppliers and local
community
 More of strategic CSR initiatives than philanthropic
activities

16. Scope for future work
 Work environment improvement for employees
 Awareness programme for suppliers regarding
environmental sustainability
 Implement environmental activities at a larger scale in
more areas
 Invest more in R&D for innovative drugs and
techniques for treatment
 Participate in community beneficial activities.